VKTX vs XENE: fair value comparison
Viking Therapeutics, Inc. and Xenon Pharmaceuticals Inc. · Updated 2026-10-19
VKTX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. XENE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, VKTX currently ranks higher by quality score.
| VKTX | XENE | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $25.17 | $33.49 |
| 12-month range | $25.17–$42.13 | $33.49–$70.96 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #274 of 301 Healthcare | #276 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Expanding |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Downtrend | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: VKTX fair value analysis · XENE fair value analysis